Genetic and Multimodal Approaches in Alzheimer's Disease

Alzheimer’s disease arises from a complex interplay between genetic predisposition and pathological cascades that disrupt neuronal networks. Recent advances in genomic science have identified both common risk alleles and rare variants that contribute to disease susceptibility, shaping polygenic risk scores for early detection and stratification. Beyond DNA sequence variation, epigenetic modifications and transcriptomic profiles provide insights into the dynamic regulation of gene expression in vulnerable brain regions. Multimodal approaches integrate genomic data with proteomic, metabolomic and neuroimaging measures to reveal mechanistic links between molecular alterations and in vivo pathology. High-throughput sequencing of post-mortem tissue has mapped cell type-specific expression signatures, while fluid biomarkers capture evolving proteinopathies in living subjects. Animal models embedding human genetic variants enable dissection of amyloid, tau and neuroimmune pathways under controlled conditions. Together, these methods afford a comprehensive framework for disentangling causal drivers from downstream phenomena, informing the development of targeted interventions and personalised medicine strategies.

Research from Nature Portfolio

Investigations into microglial activation have delineated the genetic architecture underpinning resident immune cell responses in the ageing cortex. Analyses of post-mortem tissue revealed a common variant that modulates the proportion of activated microglia and correlates with tau accumulation and cognitive decline, indicating an upstream role in disease progression. Complementary studies of hippocampal vulnerability used bulk RNA sequencing coupled with digital pathology to identify regional gene expression patterns that predict neurofibrillary tangle burden. Machine learning pinpointed key genes, including serpina5, whose expression aligns with local tau pathology, highlighting the heterogeneity of neuronal resilience and opening avenues for region-specific therapeutic targeting.

Genetic and Multimodal Approaches in Alzheimer's Disease publication trend

The graph below shows the total number of articles in genetic and multimodal approaches in alzheimer's disease across all publications each year (not limited to Nature Index journals).

Technical terms

Polygenic risk score: Aggregate measure of selected genetic variants to estimate individual disease risk.

Multi-omics: Integrated analysis of diverse molecular layers (genomic, epigenomic, transcriptomic, proteomic).

Transcriptomics: Study of global RNA expression profiles in cells or tissues.

Epigenetics: Study of heritable changes in gene function without alteration of the DNA sequence.

Microglia: Innate immune cells of the central nervous system involved in homeostasis and inflammation.

Neurofibrillary tangle: Intracellular aggregates of hyperphosphorylated tau protein characteristic of Alzheimer’s pathology.

Bulk RNA sequencing: Technique to quantify RNA expression in heterogeneous tissue samples.

Digital pathology: Computational analysis of histological images to quantify tissue features.

References

1. A novel human tau knock-in mouse model reveals interaction of Abeta and human tau under progressing cerebral amyloidosis in 5xFAD mice. Alzheimer's Research & Therapy (2023).
2. Integrative multi‐omics analysis reveals the critical role of the PBXIP1 gene in Alzheimer's disease. Aging Cell (2023).
3. Meta-Analysis of the Alzheimer’s Disease Human Brain Transcriptome and Functional Dissection in Mouse Models. Cell Reports (2020).
4. Neuropathological correlates and genetic architecture of microglial activation in elderly human brain. Nature Communications (2019).
5. Transcriptomic analysis to identify genes associated with selective hippocampal vulnerability in Alzheimer’s disease. Nature Communications (2021).